Results 91 to 100 of about 2,368 (193)

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus

JAMA Network Open
IMPORTANCENirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)–associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.OBJECTIVETo estimate the effectiveness of nirsevimab against medically ...
Xu, Hanmeng, Aparicio, Camila, Wats, Aanchal, Araujo, Barbara L., Pitzer, Virginia E., Warren, Joshua L., Shapiro, Eugene D., Niccolai, Linda M., Weinberger, Daniel M., Oliveira, Carlos R.   +9 more
openaire   +2 more sources

CDC\u2019s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants

core  

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer\u27s maternal RSV vaccine.
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Paden, Clinton, Clopper, Benjamin R, Thornburg, Natalie J, Dawood, Fatimah S, Sahni, Leila C, Englund, Janet A, Atherton, Lydia, Schlaudecker, Elizabeth P, Schuster, Jennifer E, Michaels, Marian G, Aggarwal, Megha, Stewart, Laura S, Halasa, Natasha B, Staat, Mary A, Piedra, Pedro A, Selvarangan, Rangaraj, Roychoudhury, Pavitra, Derado, Gordana, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Tannis, Ayzsa, Moline, Heidi L, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, New Vaccine Surveillance Network Collaborators   +30 more
core   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was ...
Enrico Valletta, Anthea Mariani, Claudio Cafagno, Désirée Caselli, Francesco Accomando, Claudia Rossini, Martina Fornaro, Giulia Marozzi, Melodie O. Aricò, Daniela Trotta, Letizia Lorusso, Maurizio Aricò   +11 more
core   +1 more source

Nirsevimab and other strategies for the prevention of RSV infection

Anales de Pediatría (English Edition), 2023
Antonio, Iofrío de Arce, Francisco José, Álvarez García   +1 more
openaire   +2 more sources

Talking to parents about Nirsevimab [poster]

Nirsevimab is an immunisation to protect from Respiratory syncytial virus (RSV).
Health Protection Surveillance Centre (HPSC)
core  

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

, 2023
BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season.
Greenough, Anne, Papenburg, Jesse, Keller, Christian, Pernica, Jeffrey M., Chi, Hsin, Clement, Pascale, Ahani, Bahar, Gupta, Atul, Kelly, Elizabeth J., Tuffy, Kevin M., Stein, Renato T., Aksyuk, Anastasia A., Danilenko, Daria M., Laubscher, Matt, Morehouse, Christopher, Hashimoto, Koichi, Wadia, Ushma, Richmond, Peter, Cohen, Robert, Lumertz, Magali, Heikkinen, Terho, Abram, Michael E., Yun, Ki Wook, Esser, Mark T., Choi, Eun Hwa, Palomino, María Angélica, Baraldi, Eugenio, Hosoya, Mitsuaki, de Los Santos, Abiel Homero Mascareñas, Rivero-Calle, Irene, Verwey, Charl, Komissarova, Kseniya, Wilkins, Deidre, Martinón-Torres, Federico, Kragten-Tabatabaie, Leyla, Gopalakrishnan, Vancheswaran, Chen, Albert Tian, Priante, Elena, Langedijk, Annefleur C., Nunes, Marta C., Tabor, David E., Brady, Tyler, Lebbink, Robert Jan, Bont, Louis J.   +43 more
core  

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.

JAMA Pediatr
Importance: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems.
Attaianese F, Carreras G, Trapani S, Alberti I, Aricò M, Attanasi M, Bertolucci G, Bressan S, Caselli D, Casotto V, Cazzato S, Chiarelli F, Felici E, Frusciante A, Galeone MA, Garazzino S, Giannattasio A, Gitto E, Guerriero A, Guida F, Iudica G, Lanari M, Mandato C, Manzini A, Martelli G, Milani GP, Moriondo M, Notarangelo LD, Nunziata F, Pellegrino R, Peroni D, Piccotti E, Ponticiello E, Ricci S, Rulli I, Savoia F, Silvestro E, Sisto A, Soro F, Tonetto S, Zago A, Dani C, Azzari C, Indolfi G.   +43 more
europepmc   +2 more sources